TLT Archives - BioTuesdays

Executive Moves

Theralase appoints internationally accomplished biopharma Executive, Dr. Kaouthar Lbiati, as independent board director

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) appointed Kaouthar Lbiati, M.D., as an independent director. Dr. Lbiati received a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a...

June 6, 2023

Markets

Research Capital likes Theralase data update; sees FDA breakthrough filing soon

Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given the “strong data that has...

May 31, 2023

Executive Moves

Theralase names Roger DuMoulin-White as president and CEO

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) appointed Roger DuMoulin-White as president and CEO, succeeding Arkady Mandel, M.D., Ph.D., as interim CEO. Dr. Mandel will continue as CSO and a director. Mr. DuMoulin...

May 25, 2023

Markets

Research Capital bullish on Theralase bladder cancer data

Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) data generated to date shows that Ruvidar’s efficacy is “strong and durable” for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and...

May 10, 2023

Developments

Theralase updates Phase 2 bladder cancer study

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) updated recently reported interim clinical data from a Phase 2 clinical study of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle Invasive Bladder...

May 10, 2023

Markets

Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data

April 27, 2023

Markets

Research Capital sees Theralase’s Ruvidar NMIBC as potentially better than Keytruda

Research Capital likes the potential chances of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar photodynamic therapy being better than Merck’s Keytruda for treating Bacillus Calmette-Guérin (BCG)-unresponsive...

February 23, 2023

Developments

Theralase presents Phase 2 NMIBC interim data at ASCO GU

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) presented interim data from its Phase 2 (Study II) clinical study at the American Society of Clinical Oncology (ASCO) Genito Urinary Cancer Symposium via a moderated poster...

February 23, 2023

Developments

Theralase named to TSXV 2023 Venture 50

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) was named to the TSX Venture Exchange’s 2023 Venture 50, an annual ranking of top-performing companies from five industry sectors. Theralase was recognized in the clean...

February 21, 2023

Developments

Theralase to present Phase 2 NMIBC interim data at AUA meeting

The American Urology Association has accepted for a moderated poster presentation at its annual meeting Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) interim data from its Phase 2 Bacillus Calmette Guerin unresponsive...

February 2, 2023

Tag - TLT

Theralase appoints internationally accomplished biopharma Executive, Dr. Kaouthar Lbiati, as independent board director

Research Capital likes Theralase data update; sees FDA breakthrough filing soon

Theralase names Roger DuMoulin-White as president and CEO

Research Capital bullish on Theralase bladder cancer data

Theralase updates Phase 2 bladder cancer study

Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data

Research Capital sees Theralase’s Ruvidar NMIBC as potentially better than Keytruda

Theralase presents Phase 2 NMIBC interim data at ASCO GU

Theralase named to TSXV 2023 Venture 50

Theralase to present Phase 2 NMIBC interim data at AUA meeting

General

More